The AP-1 inhibitor T-5224 suppresses MM growth both in vitro and in vivo by downregulating GPX4 and SLC7A11, effects that are reversed by ferrostatin-1, confirming a ferroptotic mechanism. This evidence concerns the gene GPX4 and Miyoshi myopathy.